Literature DB >> 21688113

Neurocognitive-genetic and neuroimaging-genetic research paradigms in schizophrenia and bipolar disorder.

Yoanna Arlina Kurnianingsih1, Carissa Nadia Kuswanto, Roger S McIntyre, Anqi Qiu, Beng Choon Ho, Kang Sim.   

Abstract

Studies examining intermediate phenotypes such as neurocognitive and neuroanatomical measures along with susceptibility genes are important for improving our understanding of the neural basis of schizophrenia (SZ) and bipolar disorder (BD). In this paper, we review extant studies involving neurocognitive-genetic and neuroimaging-genetic perspectives and particularly related to catechol-O-methyltransferase (COMT), brain-derived neurotrophic factor (BDNF) and neuregulin-1 (NRG1) genes in SZ and BD. In terms of neurocognitive-genetic investigations, COMT and BDNF are the two most studied candidate genes especially in patients with SZ. Whereas BDNF Met carriers perform worse on verbal working memory, problem solving and visuo-spatial abilities, COMT Met carriers perform better in working memory, attention, executive functioning with evidence of genotype by diagnosis interactions including high-risk individuals. In terms of genetic-structural MRI studies, patients with SZ are found to have reductions in the frontal, temporal, parietal cortices, and limbic regions, which are associated with BDNF, COMT, and NRGI genes. Genetic-functional MRI studies in psychotic disorders are sparse, especially with regard to BD. These neurocognitive and neuroimaging findings are associated with genes which are implicated in functional pathways related to neuronal signaling, inter-neuronal communication and neuroplasticity.

Entities:  

Mesh:

Year:  2011        PMID: 21688113     DOI: 10.1007/s00702-011-0672-z

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  130 in total

Review 1.  Neuroimaging of cognitive disability in schizophrenia: search for a pathophysiological mechanism.

Authors:  J D Ragland; J Yoon; M J Minzenberg; C S Carter
Journal:  Int Rev Psychiatry       Date:  2007-08

2.  Expression profile of BDNF-responsive genes during cerebellar granule cell development.

Authors:  Masaaki Sato; Kazunori Suzuki; Shigetada Nakanishi
Journal:  Biochem Biophys Res Commun       Date:  2006-01-10       Impact factor: 3.575

3.  Association of DISC1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memory.

Authors:  Tyrone D Cannon; William Hennah; Theo G M van Erp; Paul M Thompson; Jouko Lonnqvist; Matti Huttunen; Timothy Gasperoni; Annamari Tuulio-Henriksson; Tia Pirkola; Arthur W Toga; Jaakko Kaprio; John Mazziotta; Leena Peltonen
Journal:  Arch Gen Psychiatry       Date:  2005-11

Review 4.  Prefrontal neurons and the genetics of schizophrenia.

Authors:  D R Weinberger; M F Egan; A Bertolino; J H Callicott; V S Mattay; B K Lipska; K F Berman; T E Goldberg
Journal:  Biol Psychiatry       Date:  2001-12-01       Impact factor: 13.382

5.  The association between the Val158Met polymorphism of the catechol-O-methyl transferase gene and morphological abnormalities of the brain in chronic schizophrenia.

Authors:  Takashi Ohnishi; Ryota Hashimoto; Takeyuki Mori; Kiyotaka Nemoto; Yoshiya Moriguchi; Hidehiro Iida; Hiroko Noguchi; Tetsuo Nakabayashi; Hiroaki Hori; Mayu Ohmori; Ryoutaro Tsukue; Kimitaka Anami; Naotugu Hirabayashi; Seiichi Harada; Kunimasa Arima; Osamu Saitoh; Hiroshi Kunugi
Journal:  Brain       Date:  2005-12-05       Impact factor: 13.501

6.  Microarray analysis of postmortem temporal cortex from patients with schizophrenia.

Authors:  Christopher Aston; Lixin Jiang; Boris P Sokolov
Journal:  J Neurosci Res       Date:  2004-09-15       Impact factor: 4.164

Review 7.  Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence.

Authors:  P J Harrison; D R Weinberger
Journal:  Mol Psychiatry       Date:  2005-01       Impact factor: 15.992

8.  Prefrontal cognition in schizophrenia and bipolar illness in relation to Val66Met polymorphism of the brain-derived neurotrophic factor gene.

Authors:  Janusz K Rybakowski; Alina Borkowska; Maria Skibinska; Aleksandra Szczepankiewicz; Pawel Kapelski; Anna Leszczynska-Rodziewicz; Piotr M Czerski; Joanna Hauser
Journal:  Psychiatry Clin Neurosci       Date:  2006-02       Impact factor: 5.188

Review 9.  The molecular genetics of schizophrenia: new findings promise new insights.

Authors:  M J Owen; N M Williams; M C O'Donovan
Journal:  Mol Psychiatry       Date:  2004-01       Impact factor: 15.992

10.  The functional COMT polymorphism, Val 158 Met, is associated with logical memory and the personality trait intellect/imagination in a cohort of healthy 79 year olds.

Authors:  Sarah E Harris; Alan F Wright; Caroline Hayward; John M Starr; Lawrence J Whalley; Ian J Deary
Journal:  Neurosci Lett       Date:  2005-09-02       Impact factor: 3.046

View more
  10 in total

1.  Effects of the val(158)met catechol-O-methyltransferase gene polymorphism on olfactory processing in schizophrenia.

Authors:  Vidyulata Kamath; Paul J Moberg; Raquel E Gur; Richard L Doty; Bruce I Turetsky
Journal:  Behav Neurosci       Date:  2011-12-12       Impact factor: 1.912

2.  Neuregulin 1-induced AKT and ERK phosphorylation in patients with fragile X syndrome (FXS) and intellectual disability associated with obstetric complications.

Authors:  Tamás Kovács; Boglárka Bánsági; Oguz Kelemen; Szabolcs Kéri
Journal:  J Mol Neurosci       Date:  2014-02-23       Impact factor: 3.444

3.  SorCS2 is required for BDNF-dependent plasticity in the hippocampus.

Authors:  S Glerup; U Bolcho; S Mølgaard; S Bøggild; C B Vaegter; A H Smith; J L Nieto-Gonzalez; P L Ovesen; L F Pedersen; A N Fjorback; M Kjolby; H Login; M M Holm; O M Andersen; J R Nyengaard; T E Willnow; K Jensen; A Nykjaer
Journal:  Mol Psychiatry       Date:  2016-07-26       Impact factor: 15.992

4.  Association study of neuregulin-1 gene polymorphisms in a North Indian schizophrenia sample.

Authors:  Prachi Kukshal; Triptish Bhatia; A M Bhagwat; Raquel E Gur; Ruben C Gur; Smita N Deshpande; Vishwajit L Nimgaonkar; B K Thelma
Journal:  Schizophr Res       Date:  2013-01-26       Impact factor: 4.939

5.  COMT and 5-HT1A-receptor genotypes potentially affect executive functions improvement after cognitive remediation in schizophrenia.

Authors:  Marta Bosia; Margherita Bechi; Adele Pirovano; Mariachiara Buonocore; Cristina Lorenzi; Federica Cocchi; Placido Bramanti; Enrico Smeraldi; Roberto Cavallaro
Journal:  Health Psychol Behav Med       Date:  2014-04-28

6.  Is catechol-o-methyltransferase gene polymorphism a risk factor in the development of premenstrual syndrome?

Authors:  Esma Ozturk Deveci; Adnan Incebiyik; Salih Selek; Aysun Camuzcuoglu; Nese Gul Hilali; Hakan Camuzcuoglu; Mehmet Emin Erdal; Mehmet Vural
Journal:  Clin Exp Reprod Med       Date:  2014-06-30

Review 7.  The association between gene variants and longitudinal structural brain changes in psychosis: a systematic review of longitudinal neuroimaging genetics studies.

Authors:  Julia H Harari; Covadonga M Díaz-Caneja; Joost Janssen; Kenia Martínez; Bárbara Arias; Celso Arango
Journal:  NPJ Schizophr       Date:  2017-11-01

8.  GRIN2B gene and associated brain cortical white matter changes in bipolar disorder: a preliminary combined platform investigation.

Authors:  Carissa Nadia Kuswanto; Min Yi Sum; Christopher Ren Zhi Thng; Yi Bin Zhang; Guo Liang Yang; Wieslaw Lucjan Nowinski; Yih Yian Sitoh; Chian Ming Low; Kang Sim
Journal:  Biomed Res Int       Date:  2013-12-30       Impact factor: 3.411

9.  Early somatosensory processing in individuals at risk for developing psychoses.

Authors:  Florence Hagenmuller; Karsten Heekeren; Anastasia Theodoridou; Susanne Walitza; Helene Haker; Wulf Rössler; Wolfram Kawohl
Journal:  Front Behav Neurosci       Date:  2014-09-11       Impact factor: 3.558

10.  Does Cognitive Dysfunction in Bipolar Disorder Qualify as a Diagnostic Intermediate Phenotype?-A Perspective Paper.

Authors:  Lars Vedel Kessing; Kamilla Miskowiak
Journal:  Front Psychiatry       Date:  2018-10-08       Impact factor: 4.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.